α‑Mangostin Regulates Hepatic Steatosis and Obesity through SirT1-AMPK and PPARγ Pathways in High-Fat Diet-Induced Obese Mice

• Published in: Journal of agricultural and food chemistry 2015-09, Vol.63 (38), p.8399-8406
• Main Authors: Choi, Young Hee, Bae, Jin Kyung, Chae, Hee-Sung, Kim, Young-Mi, Sreymom, Yim, Han, Ling, Jang, Ha Young, Chin, Young-Won
• Format: Article
• Language: English
• Subjects: AMP-Activated Protein Kinases - genetics; AMP-Activated Protein Kinases - metabolism; Animals; Diet, High-Fat - adverse effects; Fatty Liver - drug therapy; Fatty Liver - enzymology; Fatty Liver - genetics; Fatty Liver - metabolism; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity - drug therapy; Obesity - enzymology; Obesity - genetics; Obesity - metabolism; PPAR gamma - genetics; PPAR gamma - metabolism; Sirtuin 1 - genetics; Sirtuin 1 - metabolism; Xanthones - administration & dosage
• ISSN: 0021-8561; 1520-5118
• DOI: 10.1021/acs.jafc.5b01637

Previous studies have shown that α-mangostin (α-MG) suppresses intracellular fat accumulation and stimulation of lipolysis in in vitro systems. Together with the relatively high distribution of α-MG in liver and fat, these observations made it possible to propose a plausible hypothesis that an α-MG supplement may regulate hepatic steatosis and obesity. An α-MG supplement (50 mg/kg) reduced the body weight gain (13.8%) and epidymal and retroperitoneal fat mass accumulation (15.0 and 11.3%, respectively), as well as the biochemical serum profiles such as cholesterol [TC (26.9%), LDL-C (39.1%), and HDL-C (15.3%)], glucose (30.2%), triglyceride (29.7%), and fatty acid (30.3%) levels in high-fat fed mice compared with the high-fat diet-treated group, indicating that α-MG may regulate lipid metabolism. In addition, an α-MG supplement up-regulated hepatic AMPK, SirT1, and PPARγ levels compared with the high-fat diet states, suggesting that α-MG regulates hepatic steatosis and obesity through the SirT1-AMPK and PPARγ pathways in high-fat diet-induced obese mice.